PRODUCT PIPELINE
Our Clinical Pipeline
The safety and effectiveness of IGALMI have not been established beyond 24 hours from the first dose.
The safety and efficacy of investigational agents and/or investigational uses of approved products have not been established
*Includes intermittent chronic agitation
**Regulatory path to be determined; device + drug combination to be evaluated after further evaluation of predictive algorithm
BXCL501
BXCL501 is our most advanced neuroscience clinical program. BXCL501 is a proprietary, sublingual film formulation of dexmedetomidine, a selective alpha-2 receptor agonist. It is being investigated as an acute treatment for agitation in Alzheimer’s disease, and as an adjunctive treatment for major depressive disorder.
BXCL501 has received Breakthrough Therapy and Fast Track designation for the acute treatment of agitation associated with dementia. In 2021, the Company announced positive topline results from the TRANQUILITY Phase 1b/2 trial for the acute treatment of agitation associated with dementia, including Alzheimer’s disease. Following discussions with the FDA in Q4 2021, we initiated our pivotal phase 3 program of BXCL501 for acute treatment of agitation in patients with Alzheimer’s disease. The Company has also submitted an Investigational New Drug (IND) application to evaluate BXCL501 as adjunctive treatment for major depressive disorder (MDD).
BXCL701
BXCL701 (talabostat) is an investigational, oral small molecule inhibitor of dipeptidyl peptidases (DPP)—primarily DPP 8/9 and DPP 4—which triggers inflammasome to alert and prime immune cells, leading to induction of IL-18 and IL-1ß, bridging innate & adaptive immunity. BXCL701 is currently being developed for the treatment of aggressive forms of prostate cancer and advanced solid ”hot” tumors that are refractory or treatment naïve to checkpoint inhibitors.
BXCL701 currently has two ongoing combination therapy clinical trials. The Company is conducting a Phase 1b/2 trial of BXCL701 in combination with KEYTRUDA® (pembrolizumab) for metastatic castration-resistant prostate cancer (mCRPC), in patients with adenocarcinoma and in patients with the aggressive variant small-cell neuroendocrine carcinoma.
The MD Anderson-led Phase 2 open-label basket trial is designed to evaluate the response rate of orally administered BXCL701, combined with KEYTRUDA, in two arms. Arm A is enrolling checkpoint naïve patients where checkpoint therapy is indicated (also referred to as “hot tumors”); and Arm B is enrolling patients who have progressed following checkpoint therapy alone.
